Immunovant (IMVT) Non-Current Assets (2018 - 2026)

Immunovant has reported Non-Current Assets for 9 years, with the latest figure at $8.2 million in Q1 2026.

• For the quarter ending Q1 2026, Non-Current Assets fell 4.26% year-over-year to $8.2 million; the trailing twelve-month figure through Mar 2026 stood at $36.7 million (up 41.75% YoY), and the FY2026 full-year result was $8.2 million, down 4.26% from the prior year.
• Non-Current Assets for Q1 2026 stood at $8.2 million, down from $9.5 million in the prior quarter.
• The five-year high for Non-Current Assets was $9.7 million in Q2 2025, with the low at $595000.0 in Q1 2024.
• Historically, Non-Current Assets has averaged $4.5 million across 5 years, with a median of $2.4 million in 2022.
• Annual changes were most pronounced in 2023 — Non-Current Assets tumbled 63.21% — and 2025, when it soared 1433.6%.
• Immunovant's Non-Current Assets stood at $1.8 million in 2022, then plunged by 63.21% to $670000.0 in 2023, then jumped by 1152.39% to $8.4 million in 2024, then rose by 12.66% to $9.5 million in 2025, then slipped by 13.31% to $8.2 million in 2026.
• The last three Non-Current Assets figures came in at $8.2 million (Q1 2026), $9.5 million (Q4 2025), and $9.4 million (Q3 2025), per Business Quant data.